Morgan Stanley Belite Bio, Inc Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Belite Bio, Inc stock. As of the latest transaction made, Morgan Stanley holds 507 shares of BLTE stock, worth $46,644. This represents 0.0% of its overall portfolio holdings.
Number of Shares
507
Previous 316
60.44%
Holding current value
$46,644
Previous $20,000
45.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding BLTE
# of Institutions
18Shares Held
76.4KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.2KShares$1.86 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA12.9KShares$1.18 Million0.0% of portfolio
-
Marshall Wace, LLP London, X09.49KShares$872,7120.0% of portfolio
-
Jpmorgan Chase & CO New York, NY8.16KShares$750,9040.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il7.46KShares$685,9520.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $2.29B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...